Understanding how specific proteins malfunction in neurodegenerative diseases has been hampered by the lack of precise molecular tools to study their normal roles. This limitation particularly affects research into Huntington's disease, where the massive huntingtin protein's essential functions remain poorly understood despite decades of study. New macrocyclic peptides designed with high selectivity for huntingtin represent a significant advance in chemical biology methodology. These engineered compounds demonstrate exceptional binding affinity and structural specificity, allowing researchers to probe huntingtin's cellular functions without the broad effects typical of traditional small-molecule inhibitors. The peptides underwent rigorous structure validation to confirm their precise molecular interactions. This development addresses a critical gap in neuroscience research tools, where the complexity of large neuronal proteins has historically made functional studies challenging. The availability of selective huntingtin modulators could accelerate understanding of this protein's roles in normal cellular trafficking, protein quality control, and developmental processes. Such insights are essential for distinguishing between huntingtin's protective functions and the toxic mechanisms that emerge in Huntington's disease. While these are research tools rather than therapeutics, the precision they offer represents a methodological breakthrough. The approach demonstrates how structure-based peptide design can overcome limitations of conventional pharmacological approaches in neurobiology. However, the complexity of macrocyclic peptide synthesis may limit widespread adoption, and their utility depends on whether findings translate from simplified experimental systems to the complex cellular environment where huntingtin normally operates.